Pancreatic Cancer Research

ResearcherThe University of QueenslandActive in the last 2 years

Matthew Burge

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2562-7806; OpenAlex author ID A5015610217. Sources: OpenAlex.

Their work

Papers
11 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
44
Papers, trials and grants by year

2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 2 papers · 2023: 4 papers · 2024: 1 paper · 2025: none · 2026: 2 papers

Papers 11

  1. Predicting recurrence patterns and outcomes following resection of pancreatic ductal adenocarcinoma: a contemporary real-world data cohort study. Co-author DOI 10.1097/ms9.0000000000004919↗
  2. Prognostic Value of Tumor-Infiltrating Lymphocytes in Resected Pancreatic Ductal Adenocarcinoma: A Single-Center Retrospective Australian Study. Co-author DOI 10.7759/cureus.103580↗
  3. Impact of neoadjuvant FOLFIRINOX over upfront resection in borderline resectable pancreatic cancer-an international, multicentre, real-world analysis. Co-author DOI 10.1016/j.esmorw.2023.100022↗
  4. ASCEND: a randomised, double-blinded, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel with LSTA1 in untreated metastatic pancreatic adenoc… Co-author DOI 10.1016/j.esmogo.2023.07.001↗
  5. Use and outcomes from neoadjuvant chemotherapy in borderline resectable pancreatic ductal adenocarcinoma in an Australasian population. Co-author DOI 10.1111/ajco.13807↗
  6. Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colo… Co-author DOI 10.1136/jitc-2022-006136↗
  7. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Co-author DOI 10.1200/jco.22.01134↗
  8. Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective interna… Co-author DOI 10.1016/j.ejca.2022.06.042↗
  9. Pentixafor as a theranostic agent in rectal and pancreatic adenocarcinoma: outcomes from a pilot study Last author DOI 10.21203/rs.3.rs-1274952/v2↗
  10. Supporting patients and carers affected by pancreatic cancer: A feasibility study of a counselling intervention. Co-author DOI 10.1016/j.ejon.2020.101729↗
  11. Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer. Co-author DOI 10.1093/annonc/mdz200↗

Closest collaborators

The 25 strongest of 44 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mehrdad Nikfarjam · 5 shared papers, 2019–2026 · strength 0.72
  2. Belinda Lee · 5 shared papers, 2019–2026 · strength 0.72
  3. Benjamin N. J. Thomson · 4 shared papers, 2019–2024 · strength 0.49
  4. Peter Gibbs · 4 shared papers, 2019–2024 · strength 0.49
  5. Benjamin P. T. Loveday · 2 shared papers, 2024–2026 · strength 0.39
  6. Adnan M. Nagrial · 3 shared papers, 2019–2024 · strength 0.36
  7. Niall Christopher Tebbutt · 3 shared papers, 2019–2023 · strength 0.33
  8. Marion Harris · 3 shared papers, 2019–2023 · strength 0.33
  9. David Wai-Meng Tai · 2 shared papers, 2019–2026 · strength 0.30
  10. Manju Dashini Chandrasegaram · 1 shared paper, 2026 · strength 0.30
  11. Harine Siribaddana · 1 shared paper, 2026 · strength 0.30
  12. Adrian M. Fox · 2 shared papers, 2023–2024 · strength 0.29
  13. Amitesh Chandra Roy · 1 shared paper, 2026 · strength 0.24
  14. Eden Mane · 1 shared paper, 2026 · strength 0.24
  15. Andrew Mark Haydon · 2 shared papers, 2019–2023 · strength 0.23
  16. Prasad D. Cooray · 2 shared papers, 2019–2023 · strength 0.20
  17. David Goldstein · 1 shared paper, 2023 · strength 0.16
  18. Nick Pavlakis · 1 shared paper, 2023 · strength 0.16
  19. Charlotte Lemech · 1 shared paper, 2023 · strength 0.16
  20. Yat Hang To · 1 shared paper, 2024 · strength 0.15
  21. Sam Banks · 1 shared paper, 2024 · strength 0.15
  22. Hyun Soo Ko · 1 shared paper, 2024 · strength 0.15
  23. Elizabeth Stephanie Ahern · 1 shared paper, 2022 · strength 0.14
  24. Nicholas O’Rourke · 1 shared paper, 2022 · strength 0.14
  25. David Cavallucci · 1 shared paper, 2022 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.